<DOC>
	<DOCNO>NCT01156272</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy ATS 3f® Aortic Bioprosthesis , Model 1000 ( Equine Pericardial Bioprothesis ) size 19mm patient population undergo isolated aortic valve replacement his/her native aortic valve , replacement fail prosthesis .</brief_summary>
	<brief_title>Post Market ATS 3f® Aortic Bioprosthesis , Model 1000 , Size 19mm</brief_title>
	<detailed_description>A multi-center , post market , non-randomized trial , design obtain safety efficacy data patient implant size 19mm Model 1000 heart valve . Each enrol patient follow one year post-implantation . Data collect retrospectively prospectively , patient implant 1-Jan-2009 31-Dec-2009 19mm Model 1000 . The data collect pooled data currently collect , U.S. Food Drug Administration ( FDA ) IDE Number G01284 submission U.S. FDA .</detailed_description>
	<mesh_term>Heart Valve Diseases</mesh_term>
	<criteria>The patient require isolated aortic valve replacement without concomitant procedure coronary artery bypass another valve reconstruction ATS 3f® Aortic Bioprosthesis Model 1000 ( size 19mm ) date 1Jan2009 31Dec2009 . The three remain heart valve must native tissue . The patient geographically stable willing return implant center require followup visit . The patient adequately informed consent his/her participation clinical study , require him/her , order comply protocol . The patient twenty ( 20 ) less twenty year age . The patient intravenous drug and/or alcohol abuser . The patient present implant active endocarditis . The patient present implant congenital bicuspid aortic anatomy . The patient previously implant prosthetic valve replace study valve . The patient require mitral , tricuspid pulmonic valve replacement .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>Isolated aortic valve replacement</keyword>
	<keyword>heart valve</keyword>
</DOC>